Signaturefd LLC grew its stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 92.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 14,185 shares of the company’s stock after acquiring an additional 6,810 shares during the period. Signaturefd LLC’s holdings in Takeda Pharmaceutical were worth $244,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. Eagle Global Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 30.4% in the second quarter. Eagle Global Advisors LLC now owns 136,544 shares of the company’s stock worth $2,417,000 after acquiring an additional 31,872 shares during the last quarter. Assetmark Inc. increased its position in Takeda Pharmaceutical by 443.4% during the second quarter. Assetmark Inc. now owns 7,445 shares of the company’s stock worth $132,000 after buying an additional 6,075 shares during the last quarter. Covenant Partners LLC boosted its holdings in Takeda Pharmaceutical by 7.6% during the second quarter. Covenant Partners LLC now owns 63,483 shares of the company’s stock valued at $1,124,000 after acquiring an additional 4,480 shares during the period. Creative Planning boosted its holdings in Takeda Pharmaceutical by 36.2% during the second quarter. Creative Planning now owns 51,509 shares of the company’s stock valued at $912,000 after acquiring an additional 13,679 shares during the period. Finally, NINE MASTS CAPITAL Ltd boosted its holdings in Takeda Pharmaceutical by 40.4% during the second quarter. NINE MASTS CAPITAL Ltd now owns 1,474,286 shares of the company’s stock valued at $26,146,000 after acquiring an additional 424,400 shares during the period. Institutional investors own 4.67% of the company’s stock.
Several research firms recently weighed in on TAK. Daiwa Capital Markets cut shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 15th. Jefferies Financial Group began coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, September 24th. They issued a “buy” rating for the company. ValuEngine lowered shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Zacks Investment Research raised shares of Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Finally, Cowen started coverage on shares of Takeda Pharmaceutical in a report on Friday, November 1st. They issued a “market perform” rating and a $19.50 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Takeda Pharmaceutical currently has an average rating of “Hold” and an average target price of $19.25.
Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.59 EPS for the quarter. Takeda Pharmaceutical had a net margin of 3.66% and a return on equity of 12.52%. The business had revenue of $7.56 billion for the quarter. As a group, equities analysts forecast that Takeda Pharmaceutical Co Ltd will post 1.99 earnings per share for the current fiscal year.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.